Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.41 |
| ▸ | DUT | P33316 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926297 | 1.00 | GGPS1 (0.47) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL5021145 | 1.00 | GGPS1 (0.47) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL13073400 | 1.00 | GGPS1 (0.47) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL5021079 | 0.98 | GGPS1 (0.45) | GGPS1SLC9A1DUTMGLLTOP2A | |
| SCHEMBL24975735 | 0.93 | GGPS1 (0.53) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL21318209 | 0.93 | GGPS1 (0.53) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL17167330 | 0.93 | GGPS1 (0.50) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL23619204 | 0.93 | GGPS1 (0.53) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL3540514 | 0.93 | GGPS1 (0.53) | GGPS1SLC9A1DUTPTGS1PTGS2 | |
| SCHEMBL12510483 | 0.93 | GGPS1 (0.53) | GGPS1SLC9A1DUTPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | GGPS1 1733/4885SLC9A1 3297/4885DUT 3332/4885 |
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | GGPS1 1017/4885SLC9A1 4796/4885DUT 3016/4885 |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GGPS1 1373/4885SLC9A1 4318/4885DUT 4168/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GGPS1 2366/4885SLC9A1 4816/4885DUT 3685/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | GGPS1 2545/4885SLC9A1 4254/4885DUT 3558/4885 |
| US-20170247423-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | GGPS1 1297/4885SLC9A1 3468/4885DUT 3345/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885SLC9A1 4041/4885DUT 3706/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | GGPS1 1414/4885SLC9A1 4773/4885DUT 3351/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GGPS1 1373/4885SLC9A1 4318/4885DUT 4168/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GGPS1 1228/4885SLC9A1 4826/4885DUT 2173/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | GGPS1 1228/4885SLC9A1 4826/4885DUT 2173/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | GGPS1 1548/4885SLC9A1 4830/4885DUT 3729/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GGPS1 2395/4885SLC9A1 4041/4885DUT 3706/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GGPS1 1248/4885SLC9A1 4605/4885DUT 1429/4885 |
| US-20170360881-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | VIP, FLT3, HAVCR2 | GGPS1 1106/4885SLC9A1 4839/4885DUT 4055/4885 |
| US-10300109-B2 | Peptidomimetic macrocycles | TCF4, CTNNB1, WNT1 | GGPS1 1733/4885SLC9A1 3297/4885DUT 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.